TITLE

The Safety and Efficacy of Enfuvirtide Therapy for HIV Infection in Patients with Hemophilia: A Case Series

AUTHOR(S)
Polizzotto, Mark N.; Street, Alison M.; Wright, Edwina
PUB. DATE
August 2007
SOURCE
Clinical Infectious Diseases;8/15/2007, Vol. 45 Issue 4, pe39
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The treatment of patients with human immmunodeficiency virus (HIV) infection and hemophilia involves unique challenges that may be addressed with novel antiretroviral classes. We describe the safety and efficacy of enfuvirtide therapy in 4 patients with severe hemophilia A. Although local skin reactions were common, neither local nor systemic bleeding worsened. Three patients achieved undetectable HIV loads with enfuvirtide salvage regimens.
ACCESSION #
25905777

 

Related Articles

  • Treatment of Mycobacterium avium Complex Immune Reconstitution Disease in HIV-1-Infected Individuals. Desimone, Joseph A.; Babinchak, Timothy J.; Kaulback, Kris R.; Pomerantz, Roger J. // AIDS Patient Care & STDs;Dec2003, Vol. 17 Issue 12, p617 

    Immune reconstitution disease caused by Mycobacterium avium complex (MAC) infection presenting shortly after the introduction of highly active antiretroviral therapy (HAART) has been reported with increasing frequency in persons with HIV-1 infection during the past several years. Several...

  • Predictors of Virological Outcome and Safety in Primary HIV Type 1—Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005. Hoen, Bruno; Cooper, David A.; Lampe, Fiona C.; Perrin, Luc; Clumeck, Nathan; Phillips, Andrew N.; Goh, Li-Ean; Lindback, Stefan; Sereni, Daniel; Gazzard, Brian; Montaner, Julio; Stellbrink, Hans-Jurgen; Lazzarin, Adriano; Ponscarme, Diane; Staszewski, Shlomo; Mathiesen, Lars; Smith, Don; Finlayson, Robert; Weber, Rainer; Wegmann, Laurence // Clinical Infectious Diseases;8/1/2007, Vol. 45 Issue 3, p381 

    Background. Initiation of antiretroviral therapy during primary human immunodeficiency virus (HIV)-1 infection may confer long-term benefit. Methods. After initiation of zidovudine, lamivudine, abacavir, and amprenavir therapy in patients in the QUEST cohort, predictors of virological outcome,...

  • Cost-effectiveness of highly active antiretroviral therapy in South Africa. Badri, Motasim; Maartens, Gary; Mandalia, Sundhiya; Bekker, Linda-Gail; Penrod, John R.; Platt, Robert W.; Wood, Robin; Beck, Eduard J. // PLoS Medicine;Jan2006, Vol. 3 Issue 1, pe4 

    Background: Little information exists on the impact of highly active antiretroviral therapy (HAART) on health-care provision in South Africa despite increasing scale-up of access to HAART and gradual reduction in HAART prices.Methods and Findings: Use and cost of...

  • Self-reported signs of lipodystrophy by persons living with HIV infection. Dreezen, C.; Schrooten, W.; De Mey, I.; Goebel, F. D.; Dedes, N.; Florence, E.; Colebunders, R.; Eurosupport Study Group // International Journal of STD & AIDS;Jun2002, Vol. 13 Issue 6, p393 

    Objective: To identify risk factors for the development of lipodystrophy in HIV infected patients on highly active antiretroviral therapy.Methods: A survey among patients with HIV infection using an anonymous questionnaire was conducted in 10 European countries between...

  • HIV Infection�Associated Tuberculosis: The Epidemiology and the Response. Getahun, Haileyesus; Gunneberg, Christian; Granich, Reuben; Nunn, P0ul // Clinical Infectious Diseases;5/15/2010 Supplement 3, Vol. 50, pS201 

    Of the 33.2 million persons infected with human immunodeficiency virus (HIV), one-third are estimated to also be infected with Mycobacterium tuberculosis. In 2008, there were an estimated 1.4 million new cases of tuberculosis (TB) among persons with HIV infection, and TB accounted for 26% of...

  • Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. Steigbigel, Roy T.; Cooper, David A.; Teppler, Hedy; Eron, Joseph J.; Gatell, Jose M.; Kumar, Princy N.; Rockstroh, Jurgen K.; Schechter, Mauro; Katlama, Christine; Markowitz, Martin; Yeni, Patrick; Loutfy, Mona R.; Lazzarin, Adriano; Lennox, Jeffrey L.; Clotet, Bonaventura; Jing Zhao; Hong Wan; Rhodes, Rand R.; Strohmaier, Kim M.; Barnard, Richard J. // Clinical Infectious Diseases;2/15/2010, Vol. 50 Issue 4, p605 

    BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background...

  • Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons. Pattacini, Laura; Murnane, Pamela M.; Baeten, Jared M.; Fluharty, Tayler R.; Thomas, Katherine K.; Bukusi, Elizabeth; Katabira, Elly; Mugo, Nelly; Donnell, Deborah; Lingappa, Jairam R.; Celum, Connie; Marzinke, Mark; McElrath, M. Juliana; Lund, Jennifer M. // Journal of Infectious Diseases;6/15/2015, Vol. 211 Issue 12, p1943 

    Background. Antiretroviral preexposure prophylaxis (PrEP), using daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immunodeficiency virus (HIV) prevention strategy for populations at high risk of HIV acquisition. Although the primary mode of action...

  • Reduced adherence to antiretroviral therapy among patients on antiretroviral therapy in Limpopo province, South Africa. MAKUA, T. // African Journal for Physical, Health Education, Recreation & Dan;2015Supplement, Vol. 21, p107 

    The purpose of this study was to explore the determining factors for reduced adherence to antiretroviral therapy (ART) for HIV positive patients on ART residing in Polokwane, in Limpopo Province of South Africa. This study made use of the generic qualitative research design and in-depth...

  • HIV “Elite Controllers” Are Characterized by a High Frequency of Memory CD8+CD73+ T Cells Involved in the Antigen-Specific CD8+ T-cell Response. Carrière, Matthieu; Lacabaratz, Christine; Kök, Ayrin; Benne, Clarisse; Jenabian, Mohammad-Ali; Casartelli, Nicoletta; Hüe, Sophie; Hocqueloux, Laurent; Lelièvre, Jean-Daniel; Lévy, Yves // Journal of Infectious Diseases;May2014, Vol. 209 Issue 9, p1321 

    Human immunodeficiency virus type 1 (HIV-1) infection is characterized by chronic immune activation and suppressed T-lymphocyte functions. Here we report that CD73, both a coactivator molecule of T cells and an immunosuppressive ecto-enzyme through adenosine production, is only weakly expressed...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics